Nurix Therapeutics
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: San Francisco, California, United States, North America
Region: California
Country: US
Continent: North America
About
Nurix Therapeutics is a biotechnology company focused on targeted protein degradation to develop medicines for cancer and autoimmune diseases. It leverages degraders, degrader antibody conjugates (DACs), and its DEL-AI discovery engine to create precision therapies with potentially safer, deeper, and more durable responses. The company operates globally with clinical programs and pipelines addressing multiple cancers and immune-related diseases. Nurix emphasizes translating science into clinical progress and advancing a multi-modal pipeline.
Nurix Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies for cancer and autoimmune diseases. The firm utilizes its proprietary degrader, degrader antibody conjugate, and DEL-AI platforms to create precision medicines. It advances a multi-modal pipeline through global clinical programs and strategic collaborations with major pharmaceutical firms.
Nurix, Inc
2012
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
720100000
50m-100m
ipo
NASDAQ:NRIX
nasdaq
Investors
Founders
Arthur Weiss
John Kuriyan
Michael Rape
Leadership
Technology Stack
Products
Bexobrutideg (NX-5948): An orally administered Bruton’s Tyrosine Kinase (BTK) degrader designed to treat B-cell malignancies by eliminating BTK protein, including resistant mutants.
NX-2127: An oral degrader targeting BTK for treatment of advanced B-cell malignancies, designed to eliminate disease-causing BTK proteins.
NX-1607: An oral degrader drug candidate designed to treat advanced malignancies by targeting and eliminating disease-related proteins.
Degraders: Small molecule drugs that induce degradation of disease-causing proteins by recruiting the cell’s natural protein degradation machinery.
Degrader Antibody Conjugates (DACs): Therapeutics combining antibodies with degraders to deliver targeted protein degradation with enhanced precision and safety.
DEL-AI Drug Discovery Engine: An AI-integrated platform combining DNA Encoded Libraries and machine learning to discover novel degrader drugs across diverse protein targets.
Funding rounds
Post Ipo Equity · $250M · (2025-10-22)
Post Ipo Equity · $175M · (2024-04-11)
Post Ipo Equity · $40M · (2022-07-08)